Details

Autor(en) / Beteiligte

• Yao, Z-S
• Li, C
• Liang, D
• Jiang, X-B
• Tang, J-J
• Ye, L-Q
• Yuan, K
• Ren, H
• Yang, Z-D
• Jin, D-X
• Zhang, S-C
• Ding, J-Y
• Tang, Y-C
• Xu, J-X
• Chen, K
• Xie, W-X
• Guo, D-Q
• Cui, J-C

Titel

Diagnostic and prognostic implications of serum miR-101 in osteosarcoma

Ist Teil von

• Cancer biomarkers : section A of Disease markers, 2018-01, Vol.22 (1), p.127

Ort / Verlag

Netherlands

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Blood-circulating microRNAs (miRNAs) have been reported to be used as potential biomarkers in various cancers. MiR-101 has been found to act as a tumor suppressor in many tumor types, but little is known for osteosarcoma. The purpose of this study was to investigate miR-101 expression in osteosarcoma patients and assess its correlation with clinical features and prognosis. Serum samples from 152 osteosarcoma patients and 70 healthy controls were detected using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The data showed that miR-101 expression levels were remarkably underexpressed in serum samples from osteosarcoma patients compared to controls, and the post-treatment serum miR-101 expression was significantly higher than that in the pre-treatment expression. Low serum miR-101 expression was positively associated with advanced clinical stage and distant metastasis. Receiver operating characteristic (ROC) curve analysis showed that serum miR-101 could serve as a useful marker for osteosarcoma diagnosis, with a high sensitivity and specificity. Moreover, patients with high miR-101 expression had longer overall survival and recurrence free survival than those with low miR-101 expression. In addition, both univariate and multivariate analyses showed that serum miR-101 downregulation was associated with shorter overall survival and recurrence free survival. Our present results implicated serum miR-101 might be a useful biomarker for the clinical diagnosis and prognosis of osteosarcoma.